Cantargia
Cantargia AB is a clinical-stage biotechnology enterprise headquartered in Lund, Sweden. The company focuses on the discovery and development of antibody-based therapeutics directed against the interleukin-1 receptor accessory protein for oncology and inflammatory diseases. Its lead product candidate, nadunolimab, is evaluated in clinical trials for treating various forms of solid tumors alongside standard chemotherapy regimens. Principal revenue is generated through collaborative research agreements, biopharmaceutical grants, and clinical development partnerships. The enterprise serves medical researchers, healthcare institutions, and clinical networks across Europe. Cantargia AB is publicly listed on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in Cantargia.
- Legal name
- Cantargia AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding Cantargia
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)